Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

@article{Nesto2003ThiazolidinedioneUF,
  title={Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.},
  author={Richard W. Nesto and David W. Bell and Robert Ogden Bonow and Vivian Fonseca and Scott M Grundy and Edward S. Horton and M L Winter and Daniel Porte and Clay F Semenkovich and Sidney Smith and Lawrence H. Young and Richard Kahn},
  journal={Circulation},
  year={2003},
  volume={108 23},
  pages={2941-8}
}
Diabetes is a chronic, progressively worsening disease associated with a variety of microvascular and macrovascular complications. Cardiovascular disease (CVD) is the main cause of death in these patients.1,2 During the past decade, numerous drugs have been introduced for the treatment of type 2 diabetes that, used in monotherapy or in combination therapy, are effective in lowering blood glucose to achieve glycemic goals and in reducing diabetes-related end-organ disease. Two such drugs… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

  • MA Khan, JV St Peter, JL. Xue
  • Diabetes Care
  • 2003

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

  • M St. John Sutton, M Rendell, P Dandona
  • Diabetes Care
  • 2002

Similar Papers

Loading similar papers…